CEO Touts Dexcom's Diabetes Management Success, Says CGM Launch With Verily "On Track" For 2018

Dexcom CEO Kevin Sayer spoke candidly about his organization’s recent growth and the associated “growing pains” as he laid out the company’s strategy moving forward. Despite what he calls the “most complicated product launch in our history” — the G5 continuous glucose monitor (CGM) — Sayer reported a 60 percent bump in Q1 diabetes management system revenue, gleaned by far outperforming market competitors, including Medtronic, J&J, and Abbott.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news